Evidence map›Paper›PMID 35640406›Full record

ArticleInternational immunopharmacology2022

Hematological abnormalities in immunosuppressed patients with COVID-19: Evidence from a single center. A cross sectional study.

Annesi Giacaman, Wolfrang Henriquez, Guillermo Tolosa, Aurora Prado, Roxana Jerez, Yenny Reveco, Carlos Martínez, Carlos Baumert, Belén Rodríguez, Basty Sanhueza and 2 more

Open access · greenAbstract read
In one paragraph

Article in International immunopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Annesi GiacamanLaboratory of Diagnosis and Research in Primary Immunodeficiencies Jeffrey Modell Center, Center of Translational Medicine. Medicine School, University of La Frontera, Temuco 4780000, Chile. Electronic address: annesi.giacaman@ufrontera.cl.
Wolfrang HenriquezLaboratory of Diagnosis and Research in Primary Immunodeficiencies Jeffrey Modell Center, Center of Translational Medicine. Medicine School, University of La Frontera, Temuco 4780000, Chile.
Guillermo TolosaLaboratory of Diagnosis and Research in Primary Immunodeficiencies Jeffrey Modell Center, Center of Translational Medicine. Medicine School, University of La Frontera, Temuco 4780000, Chile.
Aurora PradoLaboratory of Diagnosis and Research in Primary Immunodeficiencies Jeffrey Modell Center, Center of Translational Medicine. Medicine School, University of La Frontera, Temuco 4780000, Chile.
Roxana JerezGeneral Medicine Patient Care Unit, Hernán Henriquez Aravena Hospital, Temuco 4780000, Chile.
Yenny RevecoCentro de Salud Alemán, Angol 4650000, Chile.
Carlos MartínezDepartment of Internal medicine, Medicine School, University of La Frontera, Temuco 4780000, Chile; Rheumatology Unit, Hernán Henriquez Aravena Hospital, Temuco 4780000, Chile.
Carlos BaumertDepartment of Internal medicine, Medicine School, University of La Frontera, Temuco 4780000, Chile; Rheumatology Unit, Hernán Henriquez Aravena Hospital, Temuco 4780000, Chile.
Belén RodríguezDepartment of Internal medicine, Medicine School, University of La Frontera, Temuco 4780000, Chile; Rheumatology Unit, Hernán Henriquez Aravena Hospital, Temuco 4780000, Chile; Critical Patient Unit, Intensive Care Unit, Hernán Henriquez Aravena Hospital, Temuco 4780000, Chile.
Basty SanhuezaGastroenterology Unit, Hernán Henríquez Aravena Hospital, Temuco 4780000, Chile.
Juan José OrellanaDepartment of Public Health and Capacitación, Investigación y Gestión para la Salud Basada en Evidencias, CIGES. Medicine School. University of La Frontera, Temuco 4780000, Chile.
Jaime InostrozaLaboratory of Diagnosis and Research in Primary Immunodeficiencies Jeffrey Modell Center, Center of Translational Medicine. Medicine School, University of La Frontera, Temuco 4780000, Chile; Immunology and Flow Cytometry Laboratory, Hospital Hernan Henriquez Aravena, Temuco 4780000, Chile.
Universidad de La Frontera · CLHospital Doctor Hernán Henríquez Aravena · CLClínica Alemana · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChanges in hematological parameters in patients with COVID-19 are emerging as important features of the disease in the general population. In the present study we aimed to explore the hematological characteristics and its prevalence proportion ratio in patients with immunosuppression with COVID-19.

aimTo explore the differences between immunosuppressed and non-immunosuppressed patients, with and without COVID-19 from a hematological perspective.

methodsThis cross-sectional study reports on the baseline complete blood count in patients attending the HHA Hospital, in Chile. The study reports descriptive characteristics of the population, including sex, age, ethnicity, corticoids and biological therapy scheme and a complete report of blood test results. A total of 476 patients were enrolled in this study from October of 2020 to April 2021.

resultsFindings revels a significant increment (p value ≤ 0.001) on the median of total neutrophils and leucocytes, and in platelet-lymphocyte ratio (PLR), neutrophil- lymphocyte ratio (NLR) and monocyte-lymphocyte ratio (MLR) in immunosuppressed patients with COVID-19 (IS(+)) and immunocompetent patients with COVID-19 (IC(+)) compared with their respective controls. By contrast, a significant reduction on the median of lymphocytes, and eosinophiles was observed in IS(+) individuals compared with its controls. Also, the red blood cell count, hemoglobin, hematocrit, and mean corpuscular hemoglobin concentration were significantly reduced in IS(+) patients, whereas red blood cell, distribution width and mean corpuscular volume, were significantly higher in patients with COVID-19.

conclusionRapid blood tests, including, neutrophil, lymphocytes count and PLR, NLR can be used for early assessment and management of patients with immunosuppression.

Indexed as

COVID-19Blood PlateletsCross-Sectional StudiesHumansLymphocytesNeutrophilsRetrospective StudiesCOVID-19Immunosuppressed patientsNLRPlateletsPLRRed blood cellsWhite blood cells

Identifiers

PMID35640406
PMCPMC9110370
OpenAlexW4280590275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.